中文

易瑞生物 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-27
ItemAmountY/Y
Revenue¥0.06B+16.8%
Gross profit¥0.03B
Operating income¥-0.01B
Net income¥-0.01B
Gross margin55.8%Net margin -18.2%
Revenue Q/Q-25.7%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.03B44.2%
R&D¥0.01B16.9%
SG&A¥0.03B46.4%
Tax & other¥-0.00B-4.6%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

春晖智控曼卡龙恒而达德必集团冠中生态奥雅股份德固特博硕科技恒辉安防震裕科技嘉亨家化英力股份

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies